AU2783099A - Receptor derived peptides as modulators of receptor activity - Google Patents

Receptor derived peptides as modulators of receptor activity

Info

Publication number
AU2783099A
AU2783099A AU27830/99A AU2783099A AU2783099A AU 2783099 A AU2783099 A AU 2783099A AU 27830/99 A AU27830/99 A AU 27830/99A AU 2783099 A AU2783099 A AU 2783099A AU 2783099 A AU2783099 A AU 2783099A
Authority
AU
Australia
Prior art keywords
receptor
modulators
derived peptides
activity
receptor activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27830/99A
Inventor
Tatjana Naranda
Lennart Olsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptron
Original Assignee
Receptron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptron filed Critical Receptron
Publication of AU2783099A publication Critical patent/AU2783099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU27830/99A 1998-02-24 1999-02-23 Receptor derived peptides as modulators of receptor activity Abandoned AU2783099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2893898A 1998-02-24 1998-02-24
US09028938 1998-02-24
PCT/US1999/003910 WO1999042127A2 (en) 1998-02-24 1999-02-23 Receptor derived peptides as modulators of receptor activity

Publications (1)

Publication Number Publication Date
AU2783099A true AU2783099A (en) 1999-09-06

Family

ID=21846337

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27830/99A Abandoned AU2783099A (en) 1998-02-24 1999-02-23 Receptor derived peptides as modulators of receptor activity

Country Status (5)

Country Link
EP (1) EP1064015A2 (en)
JP (1) JP2002508160A (en)
AU (1) AU2783099A (en)
CA (1) CA2322200A1 (en)
WO (1) WO1999042127A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1149906A1 (en) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin receptor modulating peptide
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
PT1828249E (en) 2004-12-03 2011-02-25 Schering Corp Biomarkers for pre-selection of patients for anti-igf1r therapy
AU2010239125B2 (en) * 2009-04-22 2015-05-14 The Walter And Eliza Hall Institute Of Medical Research Structure of the C-terminal region of the insulin receptor alpha-chain and of the insulin-like growth factor receptor alpha-chain
CN110251668A (en) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 Low-affinity blood-brain barrier receptor antibody and application thereof
CN111732635B (en) * 2020-06-22 2022-03-22 中国医学科学院基础医学研究所 Polypeptide specifically bound with CD123 protein, polypeptide complex, co-delivery system, preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639458A (en) * 1987-03-20 1997-06-17 Regents Of The University Of California Class I MHC modulation of surface receptor activity
US5385888A (en) * 1987-03-20 1995-01-31 The Regents Of The University Of California Class I MHC modulation or surface receptor activity
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding

Also Published As

Publication number Publication date
WO1999042127A2 (en) 1999-08-26
EP1064015A2 (en) 2001-01-03
WO1999042127A3 (en) 1999-10-28
JP2002508160A (en) 2002-03-19
CA2322200A1 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
AU2482100A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2057200A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
AU6868398A (en) Mu-opiate receptor peptides
AU5522498A (en) Substituted aryl piperazines as modulators of chemokine receptor activity
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU5600100A (en) Cyclopentyl modulators of chemokine receptor activity
AU7592998A (en) Modulators of tissue regeneration
AU5270598A (en) Single sideband modulators
AU5473800A (en) Cyclopentyl modulators of chemokine receptor activity
AU5473400A (en) Cyclopentyl modulators of chemokine receptor activity
AU2091799A (en) Uses of alpha-conotoxin peptides
AU7132898A (en) Edg-1-like receptor
AU2783099A (en) Receptor derived peptides as modulators of receptor activity
AU1044799A (en) Pharmaceutical composition containing zafirlukast
AU6006898A (en) Skin preparation
AU5469400A (en) Cyclopentyl modulators of chemokine receptor activity
AU2241699A (en) Expression of proteolytically-sensitive peptides
AU6035398A (en) Human c5a-like receptor
AUPO938697A0 (en) Novel receptor
AU7522898A (en) Pseudo-peptide compounds as antagonists of neurokinines
AU7452898A (en) Cellulase preparation containing highly active cellulase sce3
AU4849299A (en) Human emr1-like g protein coupled receptor
AU8102498A (en) Preparation of diaryl-benzopyrans

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase